Comparison of the efficacy of rituximab injection and splenectomy for the treatment of chronic primary immune thrombocytopenia
10.3760/cma.j.issn.1008-6706.2019.14.017
- VernacularTitle: 利妥昔单抗注射液与脾切除术治疗成年人慢性原发免疫性血小板减少症疗效比较
- Author:
Lianjun DIAO
1
Author Information
1. Department of Hematology, the Fifth People's Hospital of Datong, Datong, Shanxi 037009 China
- Publication Type:Journal Article
- Keywords:
Thrombocytopenia;
Splenectomy;
Rituximab injection;
Reaction time;
Adverse drug reaction reporting systems;
Disease-free survival;
Adult;
Comparative effectiveness research
- From:
Chinese Journal of Primary Medicine and Pharmacy
2019;26(14):1728-1731
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To compare the efficacy and adverse reaction of rituximab injection(Rituximab) and splenectomy in the treatment of adult chronic idiopathic thrombocytopenic purpura(ITP).
Methods:From March 2013 to June 2015, 105 chronic ITP patients who were treated in the Fifth People's Hospital of Datong were divided into rituximab group(n=43) and splenectomy group(n=62). The clinical efficacy, adverse reaction and survival time of the two groups were compared.
Results:There was no statistically significant difference in baseline characteristics between the two groups.After treatment for 3 months, the response rates of the splenectomy group and the rituximab group were 91.9%(57/62), 69.8%(30/43), respectively, the difference was statistically significant between the two groups(χ2=5.04, P=0.005). After treatment for 12 months, the response rates of the splenectomy group and the rituximab group were 88.7%(55/62), 58.1%(25/43), respectively, the difference was statistically significant between the two groups (χ2=6.83, P=0.001), respectively.After treatment for 3, 12 months, the complete response rates of the splenectomy group were 82.2%(51/62), 80.6%(50/62), respectively, which were higher than those of the rituximab group [39.5%(17/43), 34.9%(15/43)] (χ2=7.25, P<0.001). There was no statistically significant difference in adverse reactions after treatment for 1 year between the two groups(P>0.05). The survival time of the splenectomy group was longer, but there was no statistically significant difference(t=4.85, P=0.18).
Conclusion:The curative effect of splenectomy in the treatment of adult ITP is better than rituximab, and the adverse reaction is not obvious between two methods.
